Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles

Core Insights - The study demonstrates that Altamira's SemaPhore™ nanoparticles effectively deliver SOD2 mRNA to the aorta, resulting in significant reductions in aorta dilation, delayed rupture, and improved survival rates in an established animal model of abdominal aortic aneurysm (AAA) [1][7][11] Company Overview - Altamira Therapeutics is focused on developing peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues, with its SemaPhore™ platform being a key component [5][7] - The company has two flagship siRNA programs in preclinical development, targeting KRAS-driven cancer and rheumatoid arthritis, and is also exploring applications for mRNA delivery [5][7] Research Findings - The study conducted by researchers from Washington University and the University of South Florida showed that systemic delivery of SOD2 mRNA via SemaPhore nanoparticles significantly reduced oxidative stress and mitigated the expansion of small AAAs [1][11] - The treatment resulted in a statistically significant improvement in survival rates (p<0.01) compared to untreated controls, indicating the potential for clinical application in managing small AAAs and preventing ruptures [1][7][11] Clinical Implications - The findings suggest that targeting oxidative stress through SOD2 mRNA delivery could be a promising therapeutic strategy for various cardiovascular disorders, including AAA and atherosclerosis [1][11] - The safety profile of the nanoparticles was favorable, with no adverse effects on major organs or hematologic parameters observed [1][11]